286 related articles for article (PubMed ID: 33502927)
1. Burkitt Lymphoma International Prognostic Index.
Olszewski AJ; Jakobsen LH; Collins GP; Cwynarski K; Bachanova V; Blum KA; Boughan KM; Bower M; Dalla Pria A; Danilov A; David KA; Diefenbach C; Ellin F; Epperla N; Farooq U; Feldman TA; Gerrie AS; Jagadeesh D; Kamdar M; Karmali R; Kassam S; Kenkre VP; Khan N; Kim SH; Klein AK; Lossos IS; Lunning MA; Martin P; Martinez-Calle N; Montoto S; Naik S; Palmisiano N; Peace D; Phillips EH; Phillips TJ; Portell CA; Reddy N; Santarsieri A; Sarraf Yazdy M; Smeland KB; Smith SE; Smith SD; Sundaram S; Zayac AS; Zhang XY; Zhu C; Cheah CY; El-Galaly TC; Evens AM
J Clin Oncol; 2021 Apr; 39(10):1129-1138. PubMed ID: 33502927
[TBL] [Abstract][Full Text] [Related]
2. Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.
Sýkorová A; Procházka V; Móciková H; Janíková A; Pytlík R; Belada D; Benešová K; Klener P; Ďuraš J; Smolej L; Campr V; Blahovcová P; Trněný M
Neoplasma; 2022 Dec; 69(6):1466-1473. PubMed ID: 36591807
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics and Outcomes of AIDS-Related Burkitt Lymphoma in China: A Retrospective Single-Center Study.
Liu R; Zhao H; Xiao G; Tao Y; Tang X; Feng L; Liao B; Liu B; Guan J; Li L; Chen Z; He H; You H
Technol Cancer Res Treat; 2024; 23():15330338231214236. PubMed ID: 38179657
[No Abstract] [Full Text] [Related]
4. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
Evens AM; Danilov A; Jagadeesh D; Sperling A; Kim SH; Vaca R; Wei C; Rector D; Sundaram S; Reddy N; Lin Y; Farooq U; D'Angelo C; Bond DA; Berg S; Churnetski MC; Godara A; Khan N; Choi YK; Yazdy M; Rabinovich E; Varma G; Karmali R; Mian A; Savani M; Burkart M; Martin P; Ren A; Chauhan A; Diefenbach C; Straker-Edwards A; Klein AK; Blum KA; Boughan KM; Smith SE; Haverkos BM; Orellana-Noia VM; Kenkre VP; Zayac A; Ramdial J; Maliske SM; Epperla N; Venugopal P; Feldman TA; Smith SD; Stadnik A; David KA; Naik S; Lossos IS; Lunning MA; Caimi P; Kamdar M; Palmisiano N; Bachanova V; Portell CA; Phillips T; Olszewski AJ; Alderuccio JP
Blood; 2021 Jan; 137(3):374-386. PubMed ID: 32663292
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels.
Kim HD; Cho H; Kim S; Lee K; Kang EH; Park JS; Park CS; Huh J; Ryu JS; Lee SW; Yoon DH; Kim SJ; Ko YH; Kim WS; Suh C
Cancer Res Treat; 2021 Jul; 53(3):847-856. PubMed ID: 33332932
[TBL] [Abstract][Full Text] [Related]
6. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
[TBL] [Abstract][Full Text] [Related]
8. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
9. The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.
Forero-Castro M; Robledo C; Lumbreras E; Benito R; Hernández-Sánchez JM; Hernández-Sánchez M; García JL; Corchete-Sánchez LA; Tormo M; Barba P; Menárguez J; Ribera J; Grande C; Escoda L; Olivier C; Carrillo E; García de Coca A; Ribera JM; Hernández-Rivas JM
Br J Haematol; 2016 Feb; 172(3):428-38. PubMed ID: 26567765
[TBL] [Abstract][Full Text] [Related]
10. [Expression of p-AKT and p-mTOR in pediatric Burkitt lymphoma and their correlation with prognosis].
Man J; Chen L; Zhai XW; Ma YY; Wang HS; Qian XW; Feng JY; Zhao J; Cao P; Lu FJ
Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):156-161. PubMed ID: 32074729
[No Abstract] [Full Text] [Related]
11. Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.
Wästerlid T; Jonsson B; Hagberg H; Jerkeman M
Leuk Lymphoma; 2011 Nov; 52(11):2090-6. PubMed ID: 21718134
[TBL] [Abstract][Full Text] [Related]
12. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Zayac AS; Evens AM; Danilov A; Smith SD; Jagadeesh D; Leslie LA; Wei C; Kim SH; Naik S; Sundaram S; Reddy N; Farooq U; Kenkre VP; Epperla N; Blum KA; Khan N; Singh D; Alderuccio JP; Godara A; Yazdy MS; Diefenbach C; Rabinovich E; Varma G; Karmali R; Shao Y; Trabolsi A; Burkart M; Martin P; Stettner S; Chauhan A; Choi YK; Straker-Edwards A; Klein A; Churnetski MC; Boughan KM; Berg S; Haverkos BM; Orellana-Noia VM; D'Angelo C; Bond DA; Maliske SM; Vaca R; Magarelli G; Sperling A; Gordon MJ; David KA; Savani M; Caimi P; Kamdar M; Lunning MA; Palmisiano N; Venugopal P; Portell CA; Bachanova V; Phillips T; Lossos IS; Olszewski AJ
Haematologica; 2021 Jul; 106(7):1932-1942. PubMed ID: 33538152
[TBL] [Abstract][Full Text] [Related]
14. [Long term efficacy of COPADM regimen in the treatment of 20 patients with Burkitt lymphoma].
Yang D; Wang P; Chen J; Li CX; Zhang Y; Chen XC; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):645-649. PubMed ID: 30180465
[No Abstract] [Full Text] [Related]
15. [Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma].
Zhang M; Wu P; Duan YL; Jin L; Yang J; Huang S; Liu Y; Hu B; Zhai XW; Wang HS; Fu Y; Li F; Yang XM; Liu AS; Qin S; Yuan XJ; Dong YS; Liu W; Zhou JW; Zhang LP; Jia YP; Wang J; Qu LJ; Dai YP; Guan GT; Sun LR; Jiang J; Liu R; Jin RM; Wang ZJ; Wang XG; Zhang BX; Chen KL; Zhuang SQ; Zhang J; Zhou CJ; Gao ZF; Zheng MC; Zhang Y
Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1011-1018. PubMed ID: 36207847
[No Abstract] [Full Text] [Related]
16. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
McMillan AK; Phillips EH; Kirkwood AA; Barrans S; Burton C; Rule S; Patmore R; Pettengell R; Ardeshna KM; Lawrie A; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC
Ann Oncol; 2020 Sep; 31(9):1251-1259. PubMed ID: 32464282
[TBL] [Abstract][Full Text] [Related]
17. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
Yang Y; Wang L; Ma Y; Han T; Huang M
Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
[TBL] [Abstract][Full Text] [Related]
18. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
19. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
[TBL] [Abstract][Full Text] [Related]
20. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.
Rizzieri DA; Johnson JL; Byrd JC; Lozanski G; Blum KA; Powell BL; Shea TC; Nattam S; Hoke E; Cheson BD; Larson RA;
Br J Haematol; 2014 Apr; 165(1):102-11. PubMed ID: 24428673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
